In this post-hoc analysis of ATTRibute-CM, incremental increases in serum TTR levels on Day 28, achieved with acoramidis, may independently predict greater reduction in risks of cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback